AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

 
• By Michael Cipriano
Pancreatic cancer
ODAC will review AZ's Lynparza for a pancreatic cancer indication.

More from US FDA Performance Tracker

More from Regulatory Trackers